Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Curemeta Logo
Curemeta Growth Score
85
CB Rank
1134400
Heat Score
46
Curemeta is a biotech company that develops therapeutic antibodies to cure metastatic cancer.
Founded
obfuscation
Private Boston, Massachusetts, United States1-10 www.curemeta.com
Biotechnology
Health Care
Medical
Overview

Curemeta
Growth Score
85
Heat Score
46

Growth Score85
-1 pts
in past quarter
Heat Score 46
-12 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Curemeta

CB Rank
1134400
Curemeta is a biotech company that develops therapeutic antibodies to cure metastatic cancer.
Founded
obfuscation
Private Boston, Massachusetts, United States1-10 www.curemeta.com
Biotechnology
Health Care
Medical

Details

Legal Name Curemeta, LLC.
Operating Status Active
Company Type For Profit
About the Company
Curemeta generates therapeutic antibodies to novel cancer targets and develops new cancer drugs to provide meaningful treatments and cures for patients with aggressive and metastatic cancers.
Phone Number +1 857 263 8343
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

CM-09
A First-in-Class Antibody-Drug-Conjugate (ADC) designed to treat patients with pancreatic and gastric cancers.
Proprietary Antibody Platform
A platform developed to generate a pipeline of antibodies targeting novel cancer markers.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Contacts 2
News
Technology
View Tech Report

Monthly Web Visits

123

IT Spend

$20.7KThis year, Curemeta is projected to spend $20.7K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
API Management Logo
API Management
76
Retirement Trends Logo
Retirement Trends
75
Dynamic Video Logo
Dynamic Video
72

Actively Used Products

5Curemeta uses 5 technology products and services including HTML5, Google Fonts, and  Adobe Fonts, according to G2 Stack.

Active Website Tech Count

3Curemeta is actively using 3 technologies for its website, according to BuiltWith. These include Common Crawl, CommonCrawl Top 50m, and  Klarna.

Total IP

3The intellectual property of Curemeta includes 3 registered patents primarily in the 'Testing' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Curemeta's headquarters? Curemeta is located in Boston, Massachusetts, United States.Who are Curemeta's competitors? Alternatives and possible competitors to Curemeta may include AbbVie, Roche, and  AstraZeneca.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(f7db04b 1)
|